NanoViricides, Inc Stock News

NanoViricides (NYSEAMERICAN:NNVC) issued its earnings results on Monday. The company reported ($0.23) EPS for the quarter, missing the Zacks consensus estimate of ($0.20) by ($0.03), Fidelity Earnings reports. Shares of NNVC stock opened at $4.76 on Thursday. The stock has a market capitalization of $54.81 million, a price-to-earnings ratio of -5.88 and a beta of []

NanoViricides, Inc. (NYSEAMERICAN:NNVC) was the target of a large drop in short interest in October. As of October 29th, there was short interest totalling 494,500 shares, a drop of 36.4% from the October 14th total of 777,000 shares. Currently, 4.5% of the companys stock are short sold. Based on an average trading volume of 2,500,000 []

SHELTON, CT / ACCESSWIRE / November 16, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel n

  NanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2 Shelton, Connecticut -- (November 15, 2021) - NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, announced today that it has developed oral gummies formulations of its Pan-Coronavir...

SHELTON, CT / ACCESSWIRE / November 15, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomed

SHELTON, CT / ACCESSWIRE / October 13, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 202

NanoViricides Inc. ( NNVC , Financial) is one of the emerging biotech companies that I have been following for a while now. Its stock price had more than doubled last month after a major update from t

Shares of NanoViricides Inc (NYSE: NNVC), a developer of antiviral therapies based on a novel nanomedicines technology, are higher Monday. What Happened: NanoViricides said its pan-Coronavirus COVID

Shelton, Connecticut -- (October 11, 2021) - NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedici

SHELTON, CT / ACCESSWIRE / October 11, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicin

Photo by Louis Reed on Unsplash Since the coronavirus pandemic started, scientists have worked to develop a vaccine to inoculate the population and stop the spread of COVID-19. The good news is they s

There were a large number of pharma companies of all sizes that began their research on developing both drugs as well as vaccines to counter the SARS-CoV-2 since 2019. Some of these companies have suc

SHELTON, Conn., Sept. 22, 2021 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomed

A Covid-19 treatment producer halted trading this morning, but news has revealed that NNVC stock is still moving upward. The post NNVC Stock: What Is Going on With Red-Hot NanoViricides Today?

Nanoviricides Inc. (NYSE:NNVC) shares are surging higher Tuesday following news of the company reporting significant advantages gained by remdesivir encapsulation within its lead COVID-19 candidate